SCHEMBL5878068

SCHEMBL5878068

C1=CC(c2ccccc2)Cc2[nH]nc(-c3cncs3)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 4/20 0.40
LMNA P02545 1/20 0.33
MAPK10 P53779 1/20 0.33
FLT3 P36888 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
HTR7 P34969 1/20 0.32
TBXAS1 P24557 1/20 0.31
DAPK3 O43293 1/20 0.30
JAK2 O60674 1/20 0.30
CSF1R P07333 1/20 0.30
RET P07949 1/20 0.30
PRKACA P17612 1/20 0.30
LTK P29376 1/20 0.30
GRK5 P34947 1/20 0.30
KDR P35968 1/20 0.30
MAP2K2 P36507 1/20 0.30
MAPK8 P45983 1/20 0.30
CSNK1A1 P48729 1/20 0.30
CDK8 P49336 1/20 0.30
CLK2 P49760 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876817 0.83 KDM4E (0.39) LMNAMAPK10HCAR2HTR7KDR
SCHEMBL5876644 0.81 MAPK10 (0.46) PIM1LMNAMAPK10FLT3HCAR2
SCHEMBL5877114 0.79 MKNK1 (0.40) PIM1LMNAMAPK10FLT3HCAR2
SCHEMBL5878102 0.78 IDO1 (0.42) PIM1LMNAMAPK10FLT3HCAR2
SCHEMBL5877175 0.78 IDO1 (0.45) PIM1LMNAMAPK10HTR7LRRK2
SCHEMBL5877629 0.76 LMNA (0.33) LMNAMAPK10HCAR2HTR7IDO1
SCHEMBL5877207 0.76 HDAC4 (0.37) PIM1LMNAMAPK10FLT3HCAR2
SCHEMBL5875946 0.76 ADORA2A (0.38) LMNAMAPK10HCAR2HTR7KDR
SCHEMBL5876901 0.74 LRRK2 (0.40) PIM1LMNAMAPK10HCAR2HTR7
SCHEMBL5875924 0.73 HCAR2 (0.38) PIM1LMNAMAPK10FLT3HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT PIM1 143/4885LMNA 4385/4885MAPK10 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.